BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dyhl-Polk A, Mikkelsen MK, Ladekarl M, Nielsen DL. Clinical Trials of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma. J Clin Med 2021;10:2662. [PMID: 34208788 DOI: 10.3390/jcm10122662] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
Number Citing Articles
1 Ao H, Xin Z, Jian Z. Liquid biopsy to identify biomarkers for immunotherapy in hepatocellular carcinoma. Biomark Res 2021;9:91. [PMID: 34930486 DOI: 10.1186/s40364-021-00348-y] [Reference Citation Analysis]
2 Zhang C, Li Y, Liu B, Ning C, Li Y, Wang Y, Li Z. Discovery of SIRT7 Inhibitor as New Therapeutic Options Against Liver Cancer. Front Cell Dev Biol 2022;9:813233. [DOI: 10.3389/fcell.2021.813233] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Hussain K, Cragg MS, Beers SA. Remodeling the Tumor Myeloid Landscape to Enhance Antitumor Antibody Immunotherapies. Cancers (Basel) 2021;13:4904. [PMID: 34638388 DOI: 10.3390/cancers13194904] [Reference Citation Analysis]
4 Qiu J, Wang Y. Effect of accelerated rehabilitation combined with enteral nutrition on gastrointestinal function recovery after hepatectomy. Support Care Cancer 2022. [PMID: 35904638 DOI: 10.1007/s00520-022-07290-1] [Reference Citation Analysis]
5 Song C, Zhang J, Wen R, Li Q, Zhou J, Xiaoli Liu, Wu Z, Lv Y, Wu R. Improved anti-hepatocellular carcinoma effect by enhanced Co-delivery of Tim-3 siRNA and sorafenib via multiple pH triggered drug-eluting nanoparticles. Mater Today Bio 2022;16:100350. [PMID: 35856043 DOI: 10.1016/j.mtbio.2022.100350] [Reference Citation Analysis]